ABSTRACT
The LIN family represents a set of conserved proteins that are pivotal in the establishment of cell polarity, the development of synapses and signal transduction processes. Its members, polarity proteins LIN2, LIN7 and LIN10, interact with diverse target proteins via the PDZ domain, SH3‐GK tandem domain and PTB domain. Through these interactions, they are actively engaged in the establishment and modulation of apical‐basal polarity. Moreover, LIN2, LIN7 and LIN10, along with their associated complex LIN2/7/10, participate in the physiological phenomena of synaptic transmission and receptor localisation. In addition, from a pathological perspective, LIN2, LIN7 and LIN10 are intricately linked to the genesis and progression of type 2 diabetes, cardiovascular disorders and a wide spectrum of tumours. This review focuses on the polarity proteins LIN2, LIN7, LIN10 and their complex. It summarises the functions of these molecular domains, systematically arranges their regulatory mechanisms in both physiological and pathological contexts and summarises the current state of research on LIN2, LIN7, LIN10 and their complex. The objective is to furnish a robust theoretical foundation for the prospective utilisation of polarity proteins and their complex as cancer markers and therapeutic targets.
Keywords: apical‐basal polarity, LIN2, LIN7, LIN10, receptor localisation, synaptic transmission, tumourigenesis
Abbreviations
- AJC
adhesion junction complex
- AMPA
α‐amino‐3‐hydroxy‐5‐methylisoxazole‐4‐propionic acid
- APBA1
adapter protein X11 alpha
- aPKC
atypical protein kinase C
- APP
amyloid precursor protein
- BLT2
leukotriene B4 receptor type 2
- CaMK
Ca2+/calmodulin‐dependent protein kinase
- CASK
calcium/calmodulin‐dependent serine protein kinase
- CDC42
cell division control 42
- CRC
colorectal cancer
- EGFR
epidermal growth factor receptor
- EMT
epithelial mesenchymal transition
- GK
guanylate kinase
- grnd
grindelwald
- HCC
hepatocellular carcinoma
- JNK
c‐Jun N‐terminal kinase
- MyoV
myosin V
- Pals1
LIN7 1 associated protein
- Patj
Pals‐associated tight junction protein
- PDZ
PSD95/Dlg/ZO1
- PIST
Golgi‐associated PDZ and coiled‐coil motif‐containing protein
- STXBP1
syntaxin binding protein 1
- TAL
Henle's loop
1. Background
Epithelial cells exhibit polarisation along the cell axis constituting the apical‐basal polarity, which acts in maintaining the morphology and function of epithelial cells, targeting proteins and lipids specifically and performing barrier and transport functions in normal physiology [1, 2]. Apical‐basal polarity is mainly established by three major polarity complexes defined by conserved polarity factors [3, 4, 5]. Additionally, multiple polarity proteins play an indispensable role in the establishment of apical‐basal polarity. The establishment of apical‐basal polarity is primarily governed by asymmetric protein accumulation, Rho GTPase signalling, asymmetric cytokinesis and the involvement of polarity determinants [6, 7, 8, 9] (Figure 1).
FIGURE 1.

Establishment and function of apical‐basal polarity. Apical‐basal polarity is primarily involved in maintaining epithelial cell morphology and establishing a physiological barrier, as well as specifically targeting and transporting proteins and lipids. The establishment and maintenance of apical‐basal polarity and its regulation are mainly dependent on these four aspects: (1) asymmetric protein accumulation; (2) Rho GTPase signalling; (3) asymmetric cytokinesis; and (4) polarity determinants.
Early investigations into apical‐basal polarity were predominantly conducted in C. elegans and Drosophila [10, 11]. Polarity proteins LIN2, LIN7 and LIN10 were first identified in C. elegans to play a critical role in the localisation of LET‐23 at the basolateral membrane, and when LIN2, LIN7 and LIN10 are mutated, the localisation of LET‐23 is altered to the apical membrane, which is mislocalised [12, 13, 14]. The LIN2/7/10 complex assembles through sequential interactions, LIN10 first recruits LIN2, which then recruits LIN7 to form a stable tripartite structure. The regulation of the LIN2/7/10 complex relies on Golgi apparatus assembly, where LIN10 plays a dominant role in recruiting LIN2 and LIN7 to the Golgi. Its core function is to mediate the targeted transport of LET‐23 EGFR to the basolateral membrane of C. elegans vulva precursor cells through this assembly process. In mammals, the complex is also involved in the localisation of polarised membrane proteins, with functions encompassing membrane anchoring, Golgi secretion and transcriptional regulation, thereby exhibiting functional diversity. In neural development, mutations in LIN2 disrupt the assembly of the complex, leading to abnormal localisation of synaptic proteins such as NMDA receptors and causing cognitive deficits. In oncogenesis, abnormal regulation of membrane localisation of receptors like EGFR by the complex enhances the invasive ability of cells [12, 15, 16]. This tripartite complex exhibits remarkable evolutionary conservation [17, 18, 19]. LIN2, LIN7 and LIN10 and their complex play important roles in five aspects: (1) formation and maintenance of basolateral polarised cell structure [20]; (2) regulation of synaptic vesicle exocytosis and synaptic connections [16]; (3) the ability to regulate polarised protein localisation: bind to LET‐23 receptor tyrosine kinase and participate in its basolateral localisation [12, 21]; (4) L27 domain: mediated targeting of NMDA receptors in neurons [17]; (5) PDZ domain: composes and maintains the protein in epithelial cells in binding with the PDZ domains of other transmembrane protein. The binding of the PDZ domain to β‐catenin maintains voltage‐gated calcium channels [12, 22]. This review systematically summarises the structure and functions of the constituent molecules of LIN2, LIN7 and LIN10, and explores their changes under physiological and pathological conditions. By integrating research findings, it consolidates the theoretical foundation for the application of polarity proteins and their complexes in the identification of cancer markers and the discovery of therapeutic targets.
2. Structure of LIN2, LIN7 and LIN10
LIN2, LIN7 and LIN10 correspond to CASK, mLIN7 and MINT1 in mammals [23, 24]. It was shown that in mammals CASK is mainly concentrated at the neuronal synapse and binds to the cell surface scaffolding proteins VELI and MINT1 to form a stable complex through the L27 domain and CaMK domain (Figure 2). MINT1 binds to the CASK‐CaMK domain with a low nanomolar dissociation constant via an extended sequence in the N‐terminal unstructured region, and structurally Ca2+/CaM is not involved in regulating the mutual binding of CASK and MINT1.
FIGURE 2.

Structure of the LIN2/7/10 complex and its members. In the LIN2/7/10 complex, LIN2 binds both LIN7 and LIN10 to each other, whereas no binding occurs between LIN7 and LIN10. LIN10 binds to the CaMK domain of LIN2 mainly through the N‐terminal unstructured region. LIN7 binds to the L27 domain of LIN2. The polarity complex exhibits striking conservatism.
2.1. Structure of LIN2
LIN2, a pluripotency gene localised on chromosome Xp11.4, encodes a calcium/calmodulin‐dependent serine protein kinase belonging to the MAGUK protein family, so it is also referred to as calcium/calmodulin‐dependent serine protein kinase (CASK), CAGH39, FGS4, EC 2.7.11.1, TNRC8, HCASK, CAMGUK MICPCH, MRXSNA and CMG. LIN2 protein is composed of five domains, including SH3, PDZ, L27, Ca2+/calmodulin‐dependent protein kinase (CaMK) and guanylate kinase (GK) [25, 26]. LIN2 functions as a conserved multidomain scaffolding protein involved in brain development, synapse formation and establishment of cell polarity by interacting with a variety of proteins. At the early stage of skin injury, LIN2 can co‐localise with Cx43 at the plasma membrane to regulate the distribution of gap junction proteins, thereby promoting wound healing [27]. In the nervous system, its SH3 and PDZ domains act as acetylcholine receptor scaffolds. By forming complexes with FRM‐3 to recruit AChRs, LIN2 mediates synaptic transmission of neurotransmitters. Whether participating in intercellular communication during wound repair in skin cells or regulating receptor aggregation on the postsynaptic membrane in neurons, LIN2 embodies its core role as a scaffold protein in organising signalling complexes across different cellular environments [28]. Mutations in the CaMK domain, an atypical kinase sensitive to Mg2+, can lead to the development of pontocerebellar hypoplasia, a disease with a microcephaly phenotype, and a life‐threatening mutation [29]. Distinct from other members of the MAGUK family of proteins, the CaMK domain located at the N‐terminal end of LIN2 has a high degree of sequence unity, and the neurexin tail can be phosphorylated by the LIN2‐CaMK domain in a kinase‐independent form that is not dependent on Mg2+ [18]. Amusingly, the CaMK domain located at the N‐terminal end of LIN2 has also been shown to interact with a brain‐specific junction protein known as Caskin 1 [24, 30]. As a member of the MAGUK protein family, calmodulin can regulate the interaction between LIN2 and other scaffolding proteins by binding to the SH3, GK domain of LIN2 in the hooked region [31].
2.2. Structure of LIN7
In mammals, the LIN7 family contains three homologous isomers, LIN7A, LIN7B and LIN7C, also named VELI1, 2, 3 or MALS1, 2, 3. Among these homologues, LIN7A and LIN7C are expressed in retinal tissues [32, 33]. LIN7 expression has been detected in renal epithelial cells. The cell‐specific markers were specifically conjugated to antibodies against the three isoforms of LIN7. In mammals, mLin7 is expressed at nectin‐based cell–cell junctions. Nectin is an immunoglobulin‐like intercellular adhesion molecule that participates in the adhesion of epithelial cells in tissues and the formation of tight junctions. The reciprocal binding between nectin and an actin filament‐binding protein named afadin is essential for the correct localisation of mLin7. However, studies have shown that mLin7 does not bind directly to nectin or afadin [34].
2.2.1. Structure of LIN7A
LIN7A is localised on chromosome 12q21.31, which encodes a protein involved in maintaining the asymmetric distribution of cell membrane receptors and channels. LIN7A/MALS1/VELI1 was found to be highly expressed mainly in the glomerulus, Henle's loop (TAL) and distal tubule. The PDZ domain of LIN7A mediates the recruitment of the α2 subunit by heterodimerisation of the β1 subunit to cell–cell contacts in HEK293 cells through binding to the PDZ ligand motif of the α2/β1 complex [35].
2.2.2. Structure of LIN7B
LIN7B is localised on chromosome 19q13.33, which encodes a protein localised in the basolateral plasma membrane with functions involved in neurotransmitter secretion and maintenance of apical‐basal polarity of epithelial cells. LIN7B/MALS2/VELI2 was expressed only in the vasa recta.
2.2.3. Structure of LIN7C
LIN7C is localised on chromosome 11p14.1, also known as FLJ11215, and encodes a protein localised mainly at the cell membrane, with a small amount distributed in the cytoplasm and nucleus. The three LIN7 isoforms are highly similar in mammals, all containing an amino‐terminal L27 domain and an accompanying PDZ domain [36]. LIN7C/MALS3/VELI3 was more abundantly expressed mainly in the collecting duct and distal tubule [37]. LIN7C, a component of the Crumbs complex, participates with Pals1, Patj and Crumbs3 in the composition of the tightly connected ventricular membrane apical [38]. Leukotriene B4 receptor type 2 (BLT2), which is predominantly distributed in epithelial cells, is transported from the Golgi to the plasma membrane to play a barrier role. In this physiological process, BLT2 transport is mainly dependent on LIN7C [39].
2.3. Structure of LIN10
LIN10, also known as APBA1 or MINT1, encodes a protein belonging to the MINT1/X11 protein family, which is defined as a PTB/PDZ domain protein, homologous to mammalian Mints [40]. LIN10 is localised on chromosome 9q21.12. The LIN10 protein contains two domains, PDZ and PTB, of which the PDZ domain has PDZ1 and PDZ2. mLin10 is the mammalian homologue of LIN10 and is abundantly present in the trans‐Golgi network. LIN10 is involved in regulating the atypical hypoxia pathway, and when oxygen activates EGL‐9E, one of the isoforms of EGL‐9, LIN10 binds to EGL‐9E and is recruited to endosomes to increase the loop of GLR‐1 AMPARs to endosomes. Under normal oxygen conditions, p38 MAPK enhanced the binding of LIN10 to EGL‐9E [40, 41].
3. The Physiological Functions of LIN2, LIN7, LIN10 and LIN2/7/10 Complex
LIN2, LIN7, LIN10 and their complex perform physiological roles in the establishment of cell polarity, synaptic transmission and basolateral receptor localisation. These physiological functions are summarised in Figure 3.
FIGURE 3.

LIN2/7/10 complex and physiological functions. LIN2/7/10 play essential roles in the physiological processes of cell polarity, synaptic transmission and basolateral receptor localisation. Reduction of Crumbs complex can be found in LIN7C‐specific knockout mice, causing renal developmental problems such as tubular dysplasia and interstitial fibrosis in mice. LIN2/7/10 complexes localised on both sides of the synapse anchor trans‐synaptic adhesion molecules to the cytoskeleton on both sides of the synapse and are involved in signal transduction at neuronal synapses. The complex also interacts with 5‐HTR to promote its localisation at the synapse. In addition, the LIN2/7/10 complex is an essential player in the localisation of LET‐23, a member of the EGFR tyrosine kinase family, at the basolateral side.
3.1. LIN2, LIN7, LIN10 and LIN2/7/10 Complex Regulate Cell Polarity
Cell polarity is widespread in plant and animal cells and microbial cells, and is the fundamental reason for the formation of biodiversity. Through polarisation, cells are able to sense and trigger timely responses from neighbouring cells and the surrounding microenvironment [42]. The regulation of cell polarity is dependent on the assembly of supramolecular complexes in multidomain scaffolding proteins. The complex composed of LIN2, LIN7 and LIN10 is essential for the maintenance of cell polarity. The LIN2/7/10 complex does not rely on its four PDZ domains, SH3‐GK tandem or PTB domain for complex assembly. Instead, these domains enable the complex to bind diverse target proteins and regulate cellular functions. As such, the LIN2/7/10 complex acts as a central regulatory hub for establishing and maintaining cell polarity [18].
LIN7 protein family members and LIN2 can also team up with the L27 domain of DLG proteins to become a complex that maintains cell polarity and mediates intercellular signalling [43]. LIN7 has been reported to form a complex with E‐cadherin and β‐catenin in epithelial cells and neurons, which are involved in the recruitment of LIN7 during the establishment of cell polarity to the intercellular junctions mediated by cadherin [44]. Renal tubular dysplasia, renal interstitial fibrosis and cystic degeneration caused by defective polarisation of renal tubular epithelial cells of mesenchymal origin were revealed in the kidneys of LIN7C‐specific knockout mice [45]. In addition, three scaffolding proteins, mammalian homologue‐2 of LIN7 (LIN7B), Pals‐associated tight junction protein (Patj) and LIN7 1 associated protein (Pals1), together form a complex that regulates apical polarity by crosstalk between the LIN2 and LIN7 domains [46]. Thus, the LIN2/7/10 complex and its members play a critical role in the maintenance and regulation of cell polarity.
3.2. LIN2, LIN7, LIN10 and LIN2/7/10 Complex Participate in Synaptic Transmission
Synapses are the basic units of neuronal signal processing in the brain, and the basis for brain function in mammals during growth depends on the formation of synapses and the transmission and dynamic response to stimulus signals [47]. The LIN2/7/10 complex of PDZ proteins is distributed on both sides of the synapse, linking trans‐synaptic adhesion molecules to the cytoskeleton to participate in neuronal signalling. Intriguingly, when the LIN2/7/10 complex component is mutated, neurons exhibit significant presynaptic defects. It has been found that liprin‐α is a major component of the purified LIN7 protein complex in the brain and that the size and morphology of the active zone are determined by liprin‐α, suggesting that the presynaptic release mechanism is linked to the active zone through this complex, thereby regulating neurotransmitter release [48, 49]. A glutamate receptor that plays an influential role in memory and learning and has synaptic plasticity is known as NMDAR, and the NMDA‐type glutamate receptor NR2 can be specifically recognised by the motor protein KIF17 by binding to the scaffolding complex LIN2/7/10 and then transporting its subunit, the NR2B vesicle, for localisation to fixed dendrites [50]. Moreover, the complex was shown to interact with 5‐HT(2C) receptors in vivo to function as a facilitator of 5‐HT(2C) receptor synaptic localisation [51]. LIN7B was evidenced to interact with Rhotekin, an effector of Rho, in vitro and in vivo to form a complex. Rho signalling regulates the interaction between LIN7B and Rhotekin. It can also be hypothesised that Rhotekin may be involved in the regulation of the LIN2/7/10 complex in the synapse, and the related mechanisms need to be explored in further studies. In addition, PIST was proved to be involved in synaptic transport by binding with Rhotekin to each other. This demonstrates that synaptic transport functions such as neurotransmitter release may depend on the competitive binding of PIST and LIN7 to Rhotekin [52]. Synaptic plasticity of AMPA‐type glutamate receptors is critically dependent on the membrane‐regulated translocation of the receptor. In the transport of AMPA receptors, one of the glutamate receptors, in the synapse, mLin10 is involved in the transport of AMPA receptors through the PDZ domain by interacting directly with glutamate receptors [53]. LIN10 is recruited by RAB‐6.2 and interacts with the GTP‐bound form of RAB‐6.2. Then LIN10, RAB‐6.2 and the retromer complex cooperate to maintain the stability of synaptic abundance by retrograde recycling of the AMPAR subunit GLR‐1 from dendrites to the Golgi apparatus [54]. Therefore, the LIN2/7/10 complex may be a crucial molecule in the synaptic transmission process.
3.3. LIN2, LIN7, LIN10 and LIN2/7/10 Complex Are Involved in Regulating Basolateral Receptor Localisation
The activity of the intracellular signalling pathway activated by the binding of epidermal growth factor receptor (EGFR) to its ligand depends on the localisation of EGFR in polarised epithelial cells [55]. The structural dimer LET‐23 is a member of the EGFR tyrosine kinase family in the nematode Hidradenitis elegans [56, 57]. LET‐23 is predominantly localised to the basement membrane of polarised vulvar epithelial cells, and a complex composed of LIN2, LIN7 and LIN10 plays an instrumental role in the basolateral localisation of LET‐23 [12, 58]. The investigators found that the complex co‐localised with LET‐23 EGFR in cytoplasmic puncta and partially overlapping Golgi bodies, and that LIN7 and LET‐23 EGFR co‐localised in the basement membrane [15, 59]. More importantly, direct binding of LIN7 to LET‐23 is necessary for proper localisation of LET‐23. Overexpression of LET‐23 can also partially redeem the vulva‐free phenotype caused by LIN2 and LIN7 mutants [60]. LIN10 participates in mediating basolateral and postsynaptic localisation pathways and has a crucial role in the epithelial and neuronal localisation of GLR‐1 [61]. LIN10 binds to amyloid precursor protein (APP) through the PTB domain and may significantly inhibit the conversion of amyloid precursor protein to amyloid β (Aβ) peptide by modifying the localisation of APP; thus, the LIN2/7/10 complex may play an influential role in neuronal APP transport and processing [62, 63, 64]. Furthermore, mammalian LIN7 coordinates basolateral targeting function through the interaction of the L27 domain with the homologous L27 domain of LIN2 [65].
4. The Pathological Functions of LIN2, LIN7 and LIN10
4.1. LIN2, LIN7 and LIN10 Impact Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease. The onset of this disease is usually caused by insulin resistance and pancreatic islet β‐cell defects [66]. As the disease progresses, the ability of pancreatic islet β‐cells in patients with T2DM to secrete insulin decreases. The secretion of insulin becomes insufficient, and the blood glucose level rises more significantly, leading to the aggravation of symptoms [67]. LIN2, LIN7 and LIN10 play roles in the secretion and regulation of insulin. Some studies have shown that the LIN2–LIN10 complex regulates the transport of Munc18‐1 to the cell membrane, thus promoting insulin secretion, and this process is extremely important. Among them, LIN2 may act as a sensor, regulator and organiser, receiving signals and activating relevant pathways. LIN10, on the other hand, serves as a regulator and a mediator. The two work in concert to jointly promote insulin secretion [68]. During the process of insulin secretion, LIN2 forms a ternary complex with LIN10 and STXBP1. By enhancing the interaction among them and mediating their transport to the plasma membrane, it promotes insulin secretion. High fatty acid stimulation reduces LIN2 expression, impairs its binding to LIN10 and its function in mediating the membrane‐targeted transport of LIN10/STXBP1, and disrupts the insulin granule exocytotic molecular axis mediated by the LIN2/LIN10/STXBP1 tripartite complex, ultimately inhibiting insulin secretion [69]. Knocking out LIN2 in mouse pancreatic islet β‐cells interferes with the transport or anchoring of insulin granules to the cell membrane, inhibits glucose‐stimulated insulin secretion and increases the blood glucose level [70]. Interestingly, the inflammatory factor IL‐1β can activate DNA methyltransferase through the iNOS pathway, causing hypermethylation in the promoter region of Cask, reducing the expression of LIN2 and then inducing the insulin secretion dysfunction of pancreatic islet β‐cells [71]. LIN2 is involved in the insulin secretion dysfunction of pancreatic islet β‐cells induced by high glucose toxicity. High glucose down‐regulates the level of LIN2, and the overexpression of LIN2 can partially improve the insulin secretion defect of cells cultured in high glucose [72]. A decrease in LIN2 expression inhibits the glucose‐stimulated insulin secretion function of INS‐1 cells induced by Ex‐4, indicating that it is involved in the insulin secretion mediated by Ex‐4. Moreover, Ex‐4 can promote the expression of LIN2 at both the transcriptional and protein levels through the cAMP/PKA pathway [73]. Han et al. found that FOXO1 mediates the dysfunction of pancreatic islet β‐cells by down‐regulating the expression of LIN2, affecting the anchoring and exocytosis of insulin granules to the cell membrane. LIN2 may regulate insulin secretion by binding to other secretion‐related cytoskeletal proteins, reducing the obstruction of F‐actin to the anchoring and fusion of insulin granules [74]. Insulin receptor substrate p53 (IRSp53) is crucial in insulin secretion. The key region for phosphorylation in the insulin‐dependent pathway is located between the N‐terminal IMD and the central SH3 domain. Tyrosine 310 is an essential site. The N‐terminal IMD is important for efficient phosphorylation and may function through dimerisation. Its phosphorylation state may affect the cellular activities related to insulin secretion [75]. IRSp53 is an adaptor protein at the membrane‐actin interface, which can link membrane deformation to F‐actin polymerisation and is key to the formation of filopodia. LIN7 can regulate IRSp53. The binding of the two is important for the formation of filopodia and neurites, and there is an interaction between them in cytoskeleton‐related activities. This provides a theoretical basis for them to regulate cytoskeleton reorganisation in pancreatic islet β‐cells and affect the transport and fusion of insulin secretion granules [76]. In addition, some studies have indicated that LIN7 can mediate the recruitment of IRSp53 to tight junctions, regulate its localisation and function. The synergistic effect of the two may be related to the regulation of the cytoskeleton during the transport and fusion of insulin secretion granules in pancreatic islet β‐cells, and abnormal insulin secretion in pancreatic islet β‐cells is closely related to the onset of diabetes [77]. LIN10 binds to Neurexin via its PDZ domain to form a complex, which recruits proteins such as LIN2 and LIN7 for plasma membrane anchoring. This complex regulates Granuphilin‐mediated insulin vesicle docking and Munc18‐1‐dependent SNARE complex assembly, and dynamically modulates vesicle fusion through Ca2+‐activated LIN2 phosphorylation upon glucose stimulation, thereby achieving precise regulation of insulin vesicle exocytosis. However, in the case of blood glucose fluctuations, the expression level of LIN10 decreases. This not only causes problems in vesicle docking but also hinders the activation of the SNARE complex, a key protein complex for cell exocytosis, interrupts the molecular communication between cells and consequently leads to insufficient insulin exocytosis [78, 79].
4.2. LIN2, LIN7 and LIN10 in Cardiovascular Diseases
The inhibition or loss of LIN2 is an important cause of cardiovascular diseases, and it is a molecular target worthy of attention in cardiology research. In both human and mouse hearts, LIN2 plays a role in regulating the activity of Ca/calmodulin‐dependent kinase II (CaMKII), and there is a close interaction between the two. When under pressure overload, the left ventricular ejection fraction of LIN2 knockout mice decreases earlier compared to that of normal mice. This is because the absence of LIN2 enhances the activity of CaMKII in mice, specifically manifested as an increase in T286 phosphorylation and a decrease in T305 phosphorylation. Eventually, it leads to systolic dysfunction, causing an increase in the mortality rate of mice under pressure overload and also increasing the susceptibility to ventricular arrhythmias. In contrast, increasing the expression of LIN2 can inhibit the activity of CaMKII, thereby improving calcium handling. For example, GLP1 receptor agonists can stimulate the expression of LIN2, thus exerting a protective effect on the heart [80]. LIN2 regulates the anterograde transport of the Nav1.5 channel through its L27B and HOOK domains and interacts with the dystrophin‐glycoprotein complex via the HOOK domain. The L27B and GUK domains regulate the functional expression of the NaV1.5 channel on the myocardial cell membrane, affecting the sodium current. LIN2 participates in the construction of the macromolecular complex scaffold through the HOOK domain. The decreased expression of LIN2 in the remodelled myocardium may affect the structural organisation of the sarcomere and the exocytosis of the Nav1.5 channel, which is related to heart diseases such as cardiac anisotropy and sodium channel‐related arrhythmias [81, 82]. In addition, LIN2 can bind to the C‐terminus of the Kir2.2 channel. It is recruited to the C‐terminus of the channel through interaction with SAP97 or LIN7 and forms a stable complex together with SAP97 and others, being associated with the Kir2 channel in the brain and heart. LIN2 co‐localises with SAP97 at the Kir2.2 and Kir2.3 channels, and its dominant negative construct will lead to the mislocalisation of the Kir2.2 channel in the cell. LIN2 is widely expressed in the heart and may affect the function of the Kir2 channel. Its abnormal function or expression changes may affect the cardiac electrophysiological process, thereby leading to the occurrence of heart diseases [83]. Currently, there are relatively few studies on the relationship between LIN7, LIN10 and cardiovascular diseases. However, considering the important role of the complex composed of LIN2, LIN7 and LIN10 in the process of cell biology, it is still necessary to conduct in‐depth research in the future on the potential functions of LIN7 and LIN10 in the cardiovascular system and their relationships with cardiovascular diseases.
4.3. LIN2, LIN7 and LIN10 in Tumourigenesis
Loss of cell polarity is commonly accompanied by abnormal cell morphogenesis, which further leads to diminished cell adhesion and excessive proliferation, which may contribute to the development of several tumours [84, 85]. It has been observed that when proteins that constitute epithelial cell polarity are dysregulated, the loss of epithelial cell polarity leads to the development of invasive tumour metastasis [86, 87, 88]. A portion of polarity proteins that act as tumour suppressor molecules, when intense oncogenic signals are targeted to disrupt these polarity proteins, the resulting polarity defects induced by polarity protein disruption may act in concert with the oncogenic signals to lead to tumour development [89] (Figure 4).
FIGURE 4.

LIN2, LIN7, LIN10 and signalling regulatory mechanisms. LIN2, LIN7 and LIN10 regulate the occurrence and progression of type 2 diabetes by binding to distinct molecules to influence insulin production and transmission. LIN2 and LIN7 are implicated in the development of cardiovascular diseases through modulating the transport of various pathways and channels. LIN2, LIN7 and LIN10 are involved in tumour development through various pathways. LIN2 acts as a pro‐oncogenic molecule and regulates downstream target molecules through the Notch pathway and JNK pathway, reducing apoptosis and promoting malignant progression of cancer cells. LIN7A acts as a downstream target molecule of various microRNAs and plays a role as a pro‐oncogenic or an inhibitory molecule in the development of cancer. Methylation‐induced reduction in the expression of LIN10 and hypermethylation‐induced reduction in the expression of LIN7C can promote the expression of β‐cadherin, which promotes cancer invasion and migration.
Interestingly, Wu et al. [18] found that a variety of LIN2 mutations in brain diseases and cancer are associated with specific structural abnormalities in the polarity proteins LIN2 and LIN10. High expression of LIN2 in pancreatic adenocarcinoma cell lines was strongly related to poor prognosis in patients with pancreatic adenocarcinoma, whereas in cholangiocarcinoma, LIN2‐negative expression was associated with significantly decreased survival and prognosis compared to LIN2‐expression‐positive patients [90, 91]. The PDZ domain of LIN2 can target binding to CD98, a negative prognostic marker for human glioblastoma cells. Constructing a chimera of the PDZ domain of LIN2 with the ribosome inactivating protein Saporin and enhancing the activity of this chimera as the number of PDZ domains increases, can effectively increase cytotoxicity and apoptosis in human glioblastoma cells, GL15 and U87 [92]. High methylation of LIN10 has also been shown to be closely associated with malignant progression of tumours. Consequently, these findings highlight the intimate association between the polarity complex and tumourigenesis (Table 1).
TABLE 1.
Expression of LIN2, LIN7 and LIN10 in different cancers and their upstream/downstream effectors.
| Name | Expression | Cancer types examined | Upstream/downstream effectors of the pathway | Cell line | References |
|---|---|---|---|---|---|
| LIN2 | Upregulated | Pancreatic adenocarcinoma | Notch pathway | Notch, CFPAC‐1 | [90, 93] |
| Upregulated | Hepatocellular carcinoma | Caspase‐7, c‐Jun N‐terminal kinase (JNK) pathway | SMMC‐7721, SK‐Hep‐1 and SMMC‐7721‐sora | [94] | |
| Upregulated | Prostate cancer | miR‐1245b‐5p | PC3, LNCaP | [95] | |
| Upregulated | Oesophageal carcinoma | Reelin | [96] | ||
| Deregulated | Cholangiocarcinoma | [91] | |||
| Deregulated | Glioblastoma | Ribosome inactivating protein Saporin, CD98 | GL15, U87 | [92] | |
| LIN7A | Upregulated | Ovarian cancer | CASC9/miR‐758‐3p/LIN7A axis | SKOV3, A2780 | [97] |
| Upregulated | Hepatocellular carcinoma | miR‐501‐3p | HCCLM3, PLC/PRF/5 | [98] | |
| Upregulated | Breast carcinomas | MEK/ERK and PI3K/AKT pathway | MCF10A, CAMA‐1 and MDA‐MB‐231 | [99] | |
| Deregulated | Neuroblastoma | DLG2‐isoform 7 | SKNAS | [43] | |
| LIN7C | Deregulated | Squamous cell carcinoma | Hypermethylation | Ca9‐22, HSC‐2, HSC‐3 and HSC‐4 | [100] |
| LIN10 | Deregulated | Colorectal cancer | Methylation | [101, 102, 103] | |
| Deregulated | Hepatocellular carcinoma | Methylation | [104] |
4.3.1. LIN2, LIN7 and LIN10 Regulate Proliferation in Cancers
A crucial factor in the unrestricted proliferation of tumours is the loss of epithelial polarity [86, 88]. The uncontrolled proliferation that occurs in Drosophila is usually caused by loss of epithelial cell polarity due to loss of function or mutations in various polarity proteins [105]. It has been shown that the polarity protein CASK is significantly upregulated in pancreatic cancer tissues, and silencing of CASK can attenuate the unrestricted proliferation of tumour cells by inhibiting the Notch pathway in pancreatic cancer cells [90, 93]. Furthermore, some investigators have identified that in Drosophila, the grindelwald (grnd) gene encoding a transmembrane protein. The cell polarity determining gene Crb co‐localises with grnd, and the altered activity of Crb and the response of downstream JNK signalling are mainly connected through the interaction of grnd with VELI, which leads to loss of polarity and uncontrolled proliferation of tumour cells [106]. The long noncoding RNA cancer susceptibility 9 called CASC9 is significantly highly expressed in ovarian cancer tissues and cells and correlates with poor prognosis in ovarian cancer patients. Hu et al. found that CASC9 and miR‐758‐3p competitively bind to downstream LIN7A, and that high CASC9 expression can effectively inhibit miR‐758‐3p expression and promote the increase of LIN7A level. In turn, the inhibitory effect on ovarian cancer progression following CASC9 reduction could be reversed by LIN7A overexpression. The CASC9/miR‐758‐3p/LIN7A axis has been shown to be involved in ovarian cancer progression, accelerating tumour proliferation in vivo [97]. Normal colorectal epithelium is generally not methylated, and CpG island methylation, as one of the pathogenic mechanisms of colorectal cancer, is clinically important for the diagnosis and treatment of colorectal cancer. Many previous studies have examined the methylation status of related genes in non‐tumour tissues and colorectal cancer tissues using methylation‐specific polymerase chain reaction technology and found that the genes with significantly increased methylation incidence included LIN10. Elevated levels of methylation of LIN10 have been shown to be closely associated with the development of colorectal cancer (CRC) and hepatocellular carcinoma (HCC), as well as with low survival rates of patients [101, 102, 103]. In addition, hepatocellular carcinoma revealed frequent methylation of all the genes tested compared to normal liver tissue. Among them, the frequency and density of methylation were higher in hepatitis C virus‐associated hepatocellular carcinomas compared with virus‐negative hepatocellular carcinomas, suggesting that viral infection caused by hepatitis C can promote the methylation process [104].
4.3.2. LIN2, LIN7 and LIN10 Regulate Apoptosis and Autophagy in Cancers
Loss of apical‐basal polarity tends to affect the regulation of apoptosis in diverse cancers [107, 108, 109]. In neuroblastoma, the protein encoded by DLG2‐isoform 7 positively regulates and increases the expression of LIN7A by binding to LIN7A, which significantly reduces the proliferative viability of neuroblastoma cells and increases apoptosis of tumour cells [43]. Additionally, hypomethylation‐induced LIN2 expression has been shown to correlate with sorafenib resistance and poor prognosis in hepatocellular carcinoma patients. Down‐regulation of LIN2 can promote apoptosis and autophagy in hepatocellular carcinoma through activation of the JNK pathway, which strengthens the effects of sorafenib [94]. Thus, polarity proteins can induce apoptosis or autophagy in cancer cells by being regulated by upstream molecules or epigenetically modified, thereby increasing patient survival and improving prognosis.
4.3.3. LIN2, LIN7 and LIN10 Regulate Metastasis in Cancers
Metastasis is a hallmark of malignancy, and numerous studies have shown that epithelial cells can acquire invasiveness and metastasis after undergoing transformation from an epithelial to a mesenchymal phenotype. Therefore, epithelial mesenchymal transition (EMT) is one of the important steps in the malignant progression of tumours. A pivotal step in the progression of metastatic cancer is the loss of apical‐basal polarity. After obtaining EMT, the shape of the cell is transformed into an elongated form, at which point the polarity of the cell is referred to as front‐back polarity. Core polarity proteins have been shown to be crucial molecules in the process of constituting and maintaining the cell adhesion junction complex (AJC). Loss of polarity proteins can disrupt cell adhesion by altering epithelial cell organisation, thereby promoting cancer invasion and metastasis [84, 89, 110, 111].
Metastasis has been implicated in pancreatic, breast and prostate cancers caused by deletion or expression of polarity proteins [112, 113, 114]. The lncRNA AATBC binds miR‐1245b‐5p as an oncogene and promotes malignant progression of prostate cancer through the miR‐1245b‐5p/LIN2 axis, and the downstream molecule LIN2 plays a pro‐oncogenic role in prostate cancer progression [95]. LIN2 and its target gene Reelin are obviously high‐expressed in human oesophageal cancer, and the upregulation of Reelin is caused by the overexpression of LIN2, which further participates in oesophageal cancer development by causing signalling pathway disorders [96]. It was found that the expression of LIN2 and Cx43 separately can inhibit cell migration, but when they are co‐expressed, the inhibition of cell migration can be eliminated [27]. In hepatocellular carcinoma, miR‐501‐3p was targeted to inhibit HCC metastasis and progression through LIN7A, a direct functional target [98]. Overexpression of LIN7A disrupts cell polarity and, via PDZ domain‐mediated interactions, activates signalling pathways such as MEK/ERK and PI3K/AKT as well as receptors including INSULIN R and AXL, thereby enhancing the proliferative and invasive capacities of breast cancer cells and contributing to carcinogenesis [99]. Additionally, hypermethylation of the CpG island region of LIN7C in oral squamous cell carcinoma resulted in down‐regulation of expression, whereas overexpression of LIN7C effectively inhibited multi‐organ metastasis in immunodeficient mice [100].
5. Summary and Perspective
This review delves deeply into the physiological and pathological functions of the polarity proteins LIN2, LIN7, LIN10 and their complex. Through the analysis and summarisation of the structural domains and physiological functions of these molecules, we have found that LIN2, LIN7, LIN10 and their complex play important roles in the establishment and maintenance of apical‐basal polarity. They are also involved in two physiological processes: synaptic transmission and receptor localisation. In addition, LIN2, LIN7 and LIN10 are associated with the pathological processes of type 2 diabetes mellitus and cardiovascular diseases. Meanwhile, they regulate the proliferation, apoptosis and metastasis of cancer cells through various pathways.
At present, partial research reports have been published on the physiological and pathological functions of LIN2, LIN7 and LIN10 individually. However, the roles of LIN2, LIN7, LIN10 and their complexes in the progression of type 2 diabetes, cardiovascular diseases and cancer require further in‐depth investigation. Additionally, current explorations of LIN2, LIN7, LIN10 and their complexes remain at the theoretical level, with no targeted therapeutic drugs having been explored or tested, and theoretical achievements still needing further clinical translation. In summary, this review deepens our understanding of the physiological and pathological roles of the polarity proteins LIN2, LIN7, LIN10 and their complexes, providing an important reference for exploring their applications in disease treatment and promoting the integration of basic research with clinical practice.
Author Contributions
Yangyang Shang: conceptualization (lead), data curation (lead), writing – original draft (lead). Xinyi Gan: conceptualization (equal), data curation (equal), writing – original draft (equal). Yue Dang: conceptualization (equal), data curation (equal), writing – original draft (equal). Jie Liu: conceptualization (equal), data curation (equal), writing – original draft (equal). Peijun Liu: conceptualization (lead), supervision (lead), writing – review and editing (lead).
Ethics Statement
The authors have nothing to report.
Consent
The authors have nothing to report.
Conflicts of Interest
The authors declare no conflicts of interest.
Acknowledgements
Figures 1, 3 and 4 were created with BioRender.com.
Shang Y., Gan X., Dang Y., Liu J., and Liu P., “The Physiological and Pathological Mechanisms of LIN2, LIN7, LIN10 and Their Tripartite Complex,” Journal of Cellular and Molecular Medicine 29, no. 15 (2025): e70794, 10.1111/jcmm.70794.
Funding: This work was supported by the National Natural Science Foundation of China (nos. 82372931, 82373389 and 82203772) and the Natural Science Basic Research Program of Shaanxi Province (no. 2024JC‐YBQN‐0897).
Data Availability Statement
No datasets were generated or analysed during the current study.
References
- 1. Karner C., Wharton K. A., and Carroll T. J., “Apical‐Basal Polarity, Wnt Signaling and Vertebrate Organogenesis,” Seminars in Cell & Developmental Biology 17 (2006): 214–222, 10.1016/j.semcdb.2006.05.007. [DOI] [PubMed] [Google Scholar]
- 2. Rodriguez‐Boulan E. and Macara I. G., “Organization and Execution of the Epithelial Polarity Programme,” Nature Reviews Molecular Cell Biology 15 (2014): 225–242, 10.1038/nrm3775. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Banks L., Pim D., and Thomas M., “Human Tumour Viruses and the Deregulation of Cell Polarity in Cancer,” Nature Reviews Cancer 12 (2012): 877–886, 10.1038/nrc3400. [DOI] [PubMed] [Google Scholar]
- 4. Buckley C. E. and St Johnston D., “Apical‐Basal Polarity and the Control of Epithelial Form and Function,” Nature Reviews Molecular Cell Biology 23 (2022): 559–577, 10.1038/s41580-022-00465-y. [DOI] [PubMed] [Google Scholar]
- 5. Rust K. and Wodarz A., “Transcriptional Control of Apical‐Basal Polarity Regulators,” International Journal of Molecular Sciences 22 (2021): 12340, 10.3390/ijms222212340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Xu S., Tyagi S., and Schedl P., “Spermatid Cyst Polarization in Drosophila Depends Upon Apkc and the CPEB Family Translational Regulator orb2,” PLoS Genetics 10 (2014): e1004380, 10.1371/journal.pgen.1004380. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Dai Y. B., Gao X., Liu D., and Gong J., “The Role of Rho GTPase Family in Cochlear Hair Cells and Hearing,” Neural Regeneration Research 18 (2023): 2167–2172, 10.4103/1673-5374.369101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Ng K., Hirani N., Bland T., et al., “Cleavage Furrow‐Directed Cortical Flows Bias PAR Polarization Pathways to Link Cell Polarity to Cell Division,” Current Biology 33 (2023): 4298–4311.e6, 10.1016/j.cub.2023.08.076. [DOI] [PubMed] [Google Scholar]
- 9. Huang Y., Chew T. G., Ge W., and Balasubramanian M. K., “Polarity Determinants Tea1p, Tea4p, and Pom1p Inhibit Division‐Septum Assembly at Cell Ends in Fission Yeast,” Developmental Cell 12 (2007): 987–996, 10.1016/j.devcel.2007.03.015. [DOI] [PubMed] [Google Scholar]
- 10. Kemphues K. J., Priess J. R., Morton D. G., and Cheng N. S., “Identification of Genes Required for Cytoplasmic Localization in Early C. elegans Embryos,” Cell 52 (1988): 311–320, 10.1016/s0092-8674(88)80024-2. [DOI] [PubMed] [Google Scholar]
- 11. Bilder D. and Perrimon N., “Localization of Apical Epithelial Determinants by the Basolateral PDZ Protein Scribble,” Nature 403 (2000): 676–680, 10.1038/35001108. [DOI] [PubMed] [Google Scholar]
- 12. Kaech S. M., Whitfield C. W., and Kim S. K., “The LIN‐2/LIN‐7/LIN‐10 Complex Mediates Basolateral Membrane Localization of the C. elegans EGF Receptor LET‐23 in Vulval Epithelial Cells,” Cell 94 (1998): 761–771, 10.1016/s0092-8674(00)81735-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Ferguson E. L. and Horvitz H. R., “Identification and Characterization of 22 Genes That Affect the Vulval Cell Lineages of the Nematode Caenorhabditis elegans ,” Genetics 110 (1985): 17–72, 10.1093/genetics/110.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Wang G. S., Hong C. J., Yen T. Y., et al., “Transcriptional Modification by a CASK‐Interacting Nucleosome Assembly Protein,” Neuron 42 (2004): 113–128, 10.1016/s0896-6273(04)00139-4. [DOI] [PubMed] [Google Scholar]
- 15. Gauthier K. D. and Rocheleau C. E., “Golgi Localization of the LIN‐2/7/10 Complex Points to a Role in Basolateral Secretion of LET‐23 EGFR in the Caenorhabditis elegans Vulval Precursor Cells,” Development 148 (2021): dev194167, 10.1242/dev.194167. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Butz S., Okamoto M., and Südhof T. C., “A Tripartite Protein Complex With the Potential to Couple Synaptic Vesicle Exocytosis to Cell Adhesion in Brain,” Cell 94 (1998): 773–782, 10.1016/s0092-8674(00)81736-5. [DOI] [PubMed] [Google Scholar]
- 17. Feng W., Long J. F., and Zhang M., “A Unified Assembly Mode Revealed by the Structures of Tetrameric L27 Domain Complexes Formed by mLin‐2/mLin‐7 and Patj/Pals1 Scaffold Proteins,” Proceedings of the National Academy of Sciences of the United States of America 102 (2005): 6861–6866, 10.1073/pnas.0409346102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Wu X., Cai Q., Chen Y., et al., “Structural Basis for the High‐Affinity Interaction Between CASK and Mint1,” Structure 28 (2020): 664–673.e3, 10.1016/j.str.2020.04.001. [DOI] [PubMed] [Google Scholar]
- 19. Hsueh Y. P., Wang T. F., Yang F. C., and Sheng M., “Nuclear Translocation and Transcription Regulation by the Membrane‐Associated Guanylate Kinase CASK/LIN‐2,” Nature 404 (2000): 298–302, 10.1038/35005118. [DOI] [PubMed] [Google Scholar]
- 20. Harris B. Z., Venkatasubrahmanyam S., and Lim W. A., “Coordinated Folding and Association of the LIN‐2, ‐7 (L27) Domain. An Obligate Heterodimerization Involved in Assembly of Signaling and Cell Polarity Complexes,” Journal of Biological Chemistry 277 (2002): 34902–34908, 10.1074/jbc.M205856200. [DOI] [PubMed] [Google Scholar]
- 21. Margolis B., Borg J. P., Straight S., and Meyer D., “The Function of PTB Domain Proteins,” Kidney International 56 (1999): 1230–1237, 10.1046/j.1523-1755.1999.00700.x. [DOI] [PubMed] [Google Scholar]
- 22. Lesage F., Hibino H., and Hudspeth A. J., “Association of Beta‐Catenin With the Alpha‐Subunit of Neuronal Large‐Conductance Ca2+‐Activated K+ Channels,” Proceedings of the National Academy of Sciences of the United States of America 101 (2004): 671–675, 10.1073/pnas.0307681100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Spiegel I., Salomon D., Erne B., Schaeren‐Wiemers N., and Peles E., “Caspr3 and Caspr4, Two Novel Members of the Caspr Family Are Expressed in the Nervous System and Interact With PDZ Domains,” Molecular and Cellular Neurosciences 20 (2002): 283–297, 10.1006/mcne.2002.1110. [DOI] [PubMed] [Google Scholar]
- 24. Tabuchi K., Biederer T., Butz S., and Sudhof T. C., “CASK Participates in Alternative Tripartite Complexes in Which Mint 1 Competes for Binding With Caskin 1, a Novel CASK‐Binding Protein,” Journal of Neuroscience 22 (2002): 4264–4273, 10.1523/jneurosci.22-11-04264.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Becker M., Mastropasqua F., Reising J. P., et al., “Presynaptic Dysfunction in CASK‐Related Neurodevelopmental Disorders,” Translational Psychiatry 10 (2020): 312, 10.1038/s41398-020-00994-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Huang T. N., Chang H. P., and Hsueh Y. P., “CASK Phosphorylation by PKA Regulates the Protein–Protein Interactions of CASK and Expression of the NMDAR2b Gene,” Journal of Neurochemistry 112 (2010): 1562–1573, 10.1111/j.1471-4159.2010.06569.x. [DOI] [PubMed] [Google Scholar]
- 27. Márquez‐Rosado L., Singh D., Rincón‐Arano H., Solan J. L., and Lampe P. D., “CASK (LIN2) Interacts With Cx43 in Wounded Skin and Their Coexpression Affects Cell Migration,” Journal of Cell Science 125 (2012): 695–702, 10.1242/jcs.084400. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Li L., Liu H., Qian K. Y., et al., “CASK and FARP Localize Two Classes of Post‐Synaptic ACh Receptors Thereby Promoting Cholinergic Transmission,” PLoS Genetics 18 (2022): e1010211, 10.1371/journal.pgen.1010211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Tibbe D., Ferle P., Krisp C., et al., “Regulation of Liprin‐α Phase Separation by CASK Is Disrupted by a Mutation in Its CaM Kinase Domain,” Life Science Alliance 5 (2022): e202201512, 10.26508/lsa.202201512. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Stafford R. L., Ear J., Knight M. J., and Bowie J. U., “The Molecular Basis of the Caskin1 and Mint1 Interaction With CASK,” Journal of Molecular Biology 412 (2011): 3–13, 10.1016/j.jmb.2011.07.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Tan B., Yatim S. M. J. M., Peng S., Gunaratne J., Hunziker W., and Ludwig A., “The Mammalian Crumbs Complex Defines a Distinct Polarity Domain Apical of Epithelial Tight Junctions,” Current Biology 30 (2020): 2791–2804.e6, 10.1016/j.cub.2020.05.032. [DOI] [PubMed] [Google Scholar]
- 32. Paarmann I., Lye M. F., Lavie A., and Konrad M., “Structural Requirements for Calmodulin Binding to Membrane‐Associated Guanylate Kinase Homologs,” Protein Science 17 (2008): 1946–1954, 10.1110/ps.035550.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Stöhr H., Molday L. L., Molday R. S., et al., “Membrane‐Associated Guanylate Kinase Proteins MPP4 and MPP5 Associate With Veli3 at Distinct Intercellular Junctions of the Neurosensory Retina,” Journal of Comparative Neurology 481 (2005): 31–41, 10.1002/cne.20367. [DOI] [PubMed] [Google Scholar]
- 34. Yamamoto Y., Mandai K., Okabe N., Hoshino T., Nakanishi H., and Takai Y., “Localization of mLin‐7 at Nectin‐Based Cell–Cell Junctions,” Oncogene 21 (2002): 2545–2554, 10.1038/sj.onc.1205335. [DOI] [PubMed] [Google Scholar]
- 35. Hochheiser J., Haase T., Busker M., Sömmer A., Kreienkamp H. J., and Behrends S., “Heterodimerization With the β(1) Subunit Directs the α(2) Subunit of Nitric Oxide‐Sensitive Guanylyl Cyclase to Calcium‐Insensitive Cell–Cell Contacts in HEK293 Cells: Interaction With Lin7a,” Biochemical Pharmacology 122 (2016): 23–32, 10.1016/j.bcp.2016.10.008. [DOI] [PubMed] [Google Scholar]
- 36. Irie M., Hata Y., Deguchi M., et al., “Isolation and Characterization of Mammalian Homologues of Caenorhabditis elegans Lin‐7: Localization at Cell–Cell Junctions,” Oncogene 18 (1999): 2811–2817, 10.1038/sj.onc.1202652. [DOI] [PubMed] [Google Scholar]
- 37. Olsen O., Wade J. B., Morin N., Bredt D. S., and Welling P. A., “Differential Localization of Mammalian Lin‐7 (MALS/Veli) PDZ Proteins in the Kidney,” American Journal of Physiology—Renal Physiology 288 (2005): F345–F352, 10.1152/ajprenal.00235.2004. [DOI] [PubMed] [Google Scholar]
- 38. Crespi A., Ferrari I., Lonati P., et al., “LIN7 Regulates the Filopodium‐ and Neurite‐Promoting Activity of IRSp53,” Journal of Cell Science 125 (2012): 4543–4554, 10.1242/jcs.106484. [DOI] [PubMed] [Google Scholar]
- 39. Hara T., Saeki K., Jinnouchi H., Kazuno S., Miura Y., and Yokomizo T., “The c‐Terminal Region of BLT2 Restricts Its Localization to the Lateral Membrane in a LIN7C‐Dependent Manner,” FASEB Journal 35 (2021): e21364, 10.1096/fj.202002640R. [DOI] [PubMed] [Google Scholar]
- 40. Park E. C., Ghose P., Shao Z., et al., “Hypoxia Regulates Glutamate Receptor Trafficking Through an HIF‐Independent Mechanism,” EMBO Journal 31 (2012): 1379–1393, 10.1038/emboj.2011.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Park E. C. and Rongo C., “The p38 MAP Kinase Pathway Modulates the Hypoxia Response and Glutamate Receptor Trafficking in Aging Neurons,” eLife 5 (2016): e12010, 10.7554/eLife.12010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Tan W., Cheng S., Li Y., et al., “Phase Separation Modulates the Assembly and Dynamics of a Polarity‐Related Scaffold‐Signaling Hub,” Nature Communications 13 (2022): 7181, 10.1038/s41467-022-35000-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Keane S., Martinsson T., Kogner P., and Ejeskär K., “The Loss of DLG2 Isoform 7/8, but Not Isoform 2, Is Critical in Advanced Staged Neuroblastoma,” Cancer Cell International 21 (2021): 170, 10.1186/s12935-021-01851-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Perego C., Vanoni C., Massari S., Longhi R., and Pietrini G., “Mammalian LIN‐7 PDZ Proteins Associate With Beta‐Catenin at the Cell–Cell Junctions of Epithelia and Neurons,” EMBO Journal 19 (2000): 3978–3989, 10.1093/emboj/19.15.3978. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Olsen O., Funke L., Long J. F., et al., “Renal Defects Associated With Improper Polarization of the CRB and DLG Polarity Complexes in MALS‐3 Knockout Mice,” Journal of Cell Biology 179 (2007): 151–164, 10.1083/jcb.200702054. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Zhang J., Yang X., Wang Z., et al., “Structure of an L27 Domain Heterotrimer From Cell Polarity Complex Patj/Pals1/Mals2 Reveals Mutually Independent L27 Domain Assembly Mode,” Journal of Biological Chemistry 287 (2012): 11132–11140, 10.1074/jbc.M111.321216. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Zeng M., Chen X., Guan D., et al., “Reconstituted Postsynaptic Density as a Molecular Platform for Understanding Synapse Formation and Plasticity,” Cell 174 (2018): 1172–1187.e16, 10.1016/j.cell.2018.06.047. [DOI] [PubMed] [Google Scholar]
- 48. Olsen O., Moore K. A., Nicoll R. A., and Bredt D. S., “Synaptic Transmission Regulated by a Presynaptic MALS/Liprin‐Alpha Protein Complex,” Current Opinion in Cell Biology 18 (2006): 223–227, 10.1016/j.ceb.2006.02.010. [DOI] [PubMed] [Google Scholar]
- 49. Olsen O., Moore K. A., Fukata M., et al., “Neurotransmitter Release Regulated by a MALS‐Liprin‐Alpha Presynaptic Complex,” Journal of Cell Biology 170 (2005): 1127–1134, 10.1083/jcb.200503011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50. Hirokawa N., Niwa S., and Tanaka Y., “Molecular Motors in Neurons: Transport Mechanisms and Roles in Brain Function, Development, and Disease,” Neuron 68 (2010): 610–638, 10.1016/j.neuron.2010.09.039. [DOI] [PubMed] [Google Scholar]
- 51. Bécamel C., Alonso G., Galéotti N., et al., “Synaptic Multiprotein Complexes Associated With 5‐HT(2C) Receptors: A Proteomic Approach,” EMBO Journal 21 (2002): 2332–2342, 10.1093/emboj/21.10.2332. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. Sudo K., Ito H., Iwamoto I., Morishita R., Asano T., and Nagata K. I., “Identification of a Cell Polarity‐Related Protein, Lin‐7B, as a Binding Partner for a Rho Effector, Rhotekin, and Their Possible Interaction in Neurons,” Neuroscience Research 56 (2006): 347–355, 10.1016/j.neures.2006.08.003. [DOI] [PubMed] [Google Scholar]
- 53. Stricker N. L. and Huganir R. L., “The PDZ Domains of mLin‐10 Regulate Its Trans‐Golgi Network Targeting and the Surface Expression of AMPA Receptors,” Neuropharmacology 45 (2003): 837–848, 10.1016/s0028-3908(03)00275-2. [DOI] [PubMed] [Google Scholar]
- 54. Zhang D., Isack N. R., Glodowski D. R., et al., “RAB‐6.2 and the Retromer Regulate Glutamate Receptor Recycling Through a Retrograde Pathway,” Journal of Cell Biology 196 (2012): 85–101, 10.1083/jcb.201104141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Haag A., Gutierrez P., Bühler A., et al., “An In Vivo EGF Receptor Localization Screen in C. elegans Identifies the Ezrin Homolog ERM‐1 as a Temporal Regulator of Signaling,” PLoS Genetics 10 (2014): e1004341, 10.1371/journal.pgen.1004341. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56. Freed D. M., Alvarado D., and Lemmon M. A., “Ligand Regulation of a Constitutively Dimeric EGF Receptor,” Nature Communications 6 (2015): 7380, 10.1038/ncomms8380. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Aroian R. V., Lesa G. M., and Sternberg P. W., “Mutations in the Caenorhabditis elegans Let‐23 EGFR‐Like Gene Define Elements Important for Cell‐Type Specificity and Function,” EMBO Journal 13 (1994): 360–366, 10.1002/j.1460-2075.1994.tb06269.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Tseng T. C., Marfatia S. M., Bryant P. J., et al., “VAM‐1: A New Member of the MAGUK Family Binds to Human Veli‐1 Through a Conserved Domain,” Biochimica et Biophysica Acta 1518 (2001): 249–259, 10.1016/s0167-4781(01)00191-9. [DOI] [PubMed] [Google Scholar]
- 59. Stetak A., Hoier E. F., Croce A., Cassata G., di Fiore P. P., and Hajnal A., “Cell Fate‐Specific Regulation of EGF Receptor Trafficking During Caenorhabditis elegans Vulval Development,” EMBO Journal 25 (2006): 2347–2357, 10.1038/sj.emboj.7601137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Simske J. S., Kaech S. M., Harp S. A., and Kim S. K., “LET‐23 Receptor Localization by the Cell Junction Protein LIN‐7 During C. elegans Vulval Induction,” Cell 85 (1996): 195–204, 10.1016/s0092-8674(00)81096-x. [DOI] [PubMed] [Google Scholar]
- 61. Rongo C., Whitfield C. W., Rodal A., Kim S. K., and Kaplan J. M., “LIN‐10 Is a Shared Component of the Polarized Protein Localization Pathways in Neurons and Epithelia,” Cell 94 (1998): 751–759, 10.1016/s0092-8674(00)81734-1. [DOI] [PubMed] [Google Scholar]
- 62. Swistowski A., Zhang Q., Orcholski M. E., et al., “Novel Mediators of Amyloid Precursor Protein Signaling,” Journal of Neuroscience 29 (2009): 15703–15712, 10.1523/jneurosci.4351-09.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Matos M. F., Xu Y., Dulubova I., et al., “Autoinhibition of Mint1 Adaptor Protein Regulates Amyloid Precursor Protein Binding and Processing,” Proceedings of the National Academy of Sciences of the United States of America 109 (2012): 3802–3807, 10.1073/pnas.1119075109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64. Borg J. P., Straight S. W., Kaech S. M., et al., “Identification of an Evolutionarily Conserved Heterotrimeric Protein Complex Involved in Protein Targeting,” Journal of Biological Chemistry 273 (1998): 31633–31636, 10.1074/jbc.273.48.31633. [DOI] [PubMed] [Google Scholar]
- 65. Alewine C., Kim B. Y., Hegde V., and Welling P. A., “Lin‐7 Targets the Kir 2.3 Channel on the Basolateral Membrane via a L27 Domain Interaction With CASK,” American Journal of Physiology—Cell Physiology 293 (2007): C1733–C1741, 10.1152/ajpcell.00323.2007. [DOI] [PubMed] [Google Scholar]
- 66. Yang M., Wei Y., Liu J., Wang Y., and Wang G., “Contributions of Hepatic Insulin Resistance and Islet β‐Cell Dysfunction to the Blood Glucose Spectrum in Newly Diagnosed Type 2 Diabetes Mellitus,” Diabetes and Metabolism Journal 49 (2025): 883–892, 10.4093/dmj.2024.0537. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67. Prentki M. and Nolan C. J., “Islet Beta Cell Failure in Type 2 Diabetes,” Journal of Clinical Investigation 116 (2006): 1802–1812, 10.1172/jci29103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68. Zhang Z., Li W., Yang G., et al., “CASK Modulates the Assembly and Function of the Mint1/Munc18‐1 Complex to Regulate Insulin Secretion,” Cell Discovery 6 (2020): 92, 10.1038/s41421-020-00216-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69. Zhang K., Wang T., Liu X., et al., “CASK, APBA1, and STXBP1 Collaborate During Insulin Secretion,” Molecular and Cellular Endocrinology 520 (2021): 111076, 10.1016/j.mce.2020.111076. [DOI] [PubMed] [Google Scholar]
- 70. Liu X., Sun P., Yuan Q., et al., “Specific Deletion of CASK in Pancreatic β Cells Affects Glucose Homeostasis and Improves Insulin Sensitivity in Obese Mice by Reducing Hyperinsulinemia,” Diabetes 71 (2022): 104–115, 10.2337/db20-1208. [DOI] [PubMed] [Google Scholar]
- 71. Wang T. Y., Liu X. J., Xie J. Y., Yuan Q. Z., and Wang Y., “Cask Methylation Involved in the Injury of Insulin Secretion Function Caused by Interleukin1‐β,” Journal of Cellular and Molecular Medicine 24 (2020): 14247–14256, 10.1111/jcmm.16041. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72. Wang Y., Hao N., Lin H., Wang T., Xie J., and Yuan Y., “Down‐Regulation of CASK in Glucotoxicity‐Induced Insulin Dysfunction in Pancreatic β Cells,” Acta Biochimica et Biophysica Sinica Shanghai 50 (2018): 281–287, 10.1093/abbs/gmx139. [DOI] [PubMed] [Google Scholar]
- 73. Zhu Z. Q., Wang D., Xiang D., Yuan Y. X., and Wang Y., “Calcium/Calmodulin‐Dependent Serine Protein Kinase Is Involved in Exendin‐4‐Induced Insulin Secretion in INS‐1 Cells,” Metabolism 63 (2014): 120–126, 10.1016/j.metabol.2013.09.009. [DOI] [PubMed] [Google Scholar]
- 74. Wang Y., Lin H., Hao N., et al., “Forkhead Box O1 Mediates Defects in Palmitate‐Induced Insulin Granule Exocytosis by Downregulation of Calcium/Calmodulin‐Dependent Serine Protein Kinase Expression in INS‐1 Cells,” Diabetologia 58 (2015): 1272–1281, 10.1007/s00125-015-3561-4. [DOI] [PubMed] [Google Scholar]
- 75. Heung M. Y., Visegrady B., Fütterer K., and Machesky L. M., “Identification of the Insulin‐Responsive Tyrosine Phosphorylation Sites on IRSp53,” European Journal of Cell Biology 87 (2008): 699–708, 10.1016/j.ejcb.2008.02.010. [DOI] [PubMed] [Google Scholar]
- 76. Ferrari I., Crespi A., Scita G., and Pietrini G., “LIN7‐IRSp53: A Novel Pathway for Filopodia and Neurite Formation?,” Communicative & Integrative Biology 5 (2012): 631–633, 10.4161/cib.21686. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77. Massari S., Perego C., Padovano V., et al., “LIN7 Mediates the Recruitment of IRSp53 to Tight Junctions,” Traffic 10 (2009): 246–257, 10.1111/j.1600-0854.2008.00854.x. [DOI] [PubMed] [Google Scholar]
- 78. Suckow A. T., Comoletti D., Waldrop M. A., et al., “Expression of Neurexin, Neuroligin, and Their Cytoplasmic Binding Partners in the Pancreatic Beta‐Cells and the Involvement of Neuroligin in Insulin Secretion,” Endocrinology 149 (2008): 6006–6017, 10.1210/en.2008-0274. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79. Shah D. P., Joshi M., Shedaliya U., and Krishnakumar A., “Recurrent Hypoglycemia Dampens Functional Regulation Mediated via Neurexin‐1, Neuroligin‐2 and Mint‐1 Docking Proteins: Intensified Complications During Diabetes,” Cellular Signalling 104 (2023): 110582, 10.1016/j.cellsig.2022.110582. [DOI] [PubMed] [Google Scholar]
- 80. Mustroph J., Sag C. M., Bähr F., et al., “Loss of CASK Accelerates Heart Failure Development,” Circulation Research 128 (2021): 1139–1155, 10.1161/circresaha.120.318170. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81. Beuriot A., Eichel C. A., Dilanian G., et al., “Distinct Calcium/Calmodulin‐Dependent Serine Protein Kinase Domains Control Cardiac Sodium Channel Membrane Expression and Focal Adhesion Anchoring,” Heart Rhythm 17 (2020): 786–794, 10.1016/j.hrthm.2019.12.019. [DOI] [PubMed] [Google Scholar]
- 82. Eichel C. A., Beuriot A., Chevalier M. Y. E., et al., “Lateral Membrane‐Specific MAGUK CASK Down‐Regulates NaV1.5 Channel in Cardiac Myocytes,” Circulation Research 119 (2016): 544–556, 10.1161/circresaha.116.309254. [DOI] [PubMed] [Google Scholar]
- 83. Leonoudakis D., Conti L. R., Anderson S., et al., “Protein Trafficking and Anchoring Complexes Revealed by Proteomic Analysis of Inward Rectifier Potassium Channel (Kir2.X)‐Associated Proteins,” Journal of Biological Chemistry 279 (2004): 22331–22346, 10.1074/jbc.M400285200. [DOI] [PubMed] [Google Scholar]
- 84. Feigin M. E. and Muthuswamy S. K., “Polarity Proteins Regulate Mammalian Cell–Cell Junctions and Cancer Pathogenesis,” Current Opinion in Cell Biology 21 (2009): 694–700, 10.1016/j.ceb.2009.07.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85. Rejon C., Al‐Masri M., and McCaffrey L., “Cell Polarity Proteins in Breast Cancer Progression,” Journal of Cellular Biochemistry 117 (2016): 2215–2223, 10.1002/jcb.25553. [DOI] [PubMed] [Google Scholar]
- 86. Martin‐Belmonte F. and Perez‐Moreno M., “Epithelial Cell Polarity, Stem Cells and Cancer,” Nature Reviews Cancer 12 (2011): 23–38, 10.1038/nrc3169. [DOI] [PubMed] [Google Scholar]
- 87. Thottacherry J. J., Chen J., and Johnston D. S., “Apical‐Basal Polarity in the Gut,” Seminars in Cell & Developmental Biology 150–151 (2023): 15–22, 10.1016/j.semcdb.2022.12.007. [DOI] [PubMed] [Google Scholar]
- 88. Ellenbroek S. I., Iden S., and Collard J. G., “Cell Polarity Proteins and Cancer,” Seminars in Cancer Biology 22 (2012): 208–215, 10.1016/j.semcancer.2012.02.012. [DOI] [PubMed] [Google Scholar]
- 89. Royer C. and Lu X., “Epithelial Cell Polarity: A Major Gatekeeper Against Cancer?,” Cell Death and Differentiation 18 (2011): 1470–1477, 10.1038/cdd.2011.60. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90. Meng M., Liu S., Wang C., Gu X., Linghu E., and Xue X., “Mass Spectrum Analysis of Membrane Proteins Reveals That CASK, CD36 and EPB42 Are Differentially Expressed in Pancreatic Adenocarcinoma,” Oncology Letters 20 (2020): 376, 10.3892/ol.2020.12239. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91. Da Z., Gao L., Su G., et al., “Bioinformatics Combined With Quantitative Proteomics Analyses and Identification of Potential Biomarkers in Cholangiocarcinoma,” Cancer Cell International 20 (2020): 130, 10.1186/s12935-020-01212-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92. Giansanti F., Sabatini D., Pennacchio M. R., et al., “PDZ Domain in the Engineering and Production of a Saporin Chimeric Toxin as a Tool for Targeting Cancer Cells,” Journal of Cellular Biochemistry 116 (2015): 1256–1266, 10.1002/jcb.25080. [DOI] [PubMed] [Google Scholar]
- 93. Qu J., Zhou Y., Li Y., Yu J., and Wang W., “CASK Regulates Notch Pathway and Functions as a Tumor Promoter in Pancreatic Cancer,” Archives of Biochemistry and Biophysics 701 (2021): 108789, 10.1016/j.abb.2021.108789. [DOI] [PubMed] [Google Scholar]
- 94. Ding B., Bao C., Jin L., Xu L., Fan W., and Lou W., “CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death,” Frontiers in Oncology 11 (2021): 681683, 10.3389/fonc.2021.681683. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95. Zhang W., Liu Q., Zhao J., Wang T., and Wang J., “Long Noncoding RNA AATBC Promotes the Proliferation and Migration of Prostate Cancer Cell Through miR‐1245b‐5p/CASK Axis,” Cancer Management and Research 13 (2021): 5091–5100, 10.2147/cmar.S310529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96. Wang Q., Lu J., Yang C., et al., “CASK and Its Target Gene Reelin Were Co‐Upregulated in Human Esophageal Carcinoma,” Cancer Letters 179 (2002): 71–77, 10.1016/s0304-3835(01)00846-1. [DOI] [PubMed] [Google Scholar]
- 97. Hu X., Li Y., Kong D., Hu L., Liu D., and Wu J., “Long Noncoding RNA CASC9 Promotes LIN7A Expression via miR‐758‐3p to Facilitate the Malignancy of Ovarian Cancer,” Journal of Cellular Physiology 234 (2019): 10800–10808, 10.1002/jcp.27903. [DOI] [PubMed] [Google Scholar]
- 98. Luo C., Yin D., Zhan H., et al., “MicroRNA‐501‐3p Suppresses Metastasis and Progression of Hepatocellular Carcinoma Through Targeting LIN7A,” Cell Death & Disease 9 (2018): 535, 10.1038/s41419-018-0577-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99. Gruel N., Fuhrmann L., Lodillinsky C., et al., “LIN7A Is a Major Determinant of Cell‐Polarity Defects in Breast Carcinomas,” Breast Cancer Research 18 (2016): 23, 10.1186/s13058-016-0680-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100. Onda T., Uzawa K., Nakashima D., et al., “Lin‐7C/VELI3/MALS‐3: An Essential Component in Metastasis of Human Squamous Cell Carcinoma,” Cancer Research 67 (2007): 9643–9648, 10.1158/0008-5472.Can-07-1911. [DOI] [PubMed] [Google Scholar]
- 101. Garrity‐Park M. M., E. V. Loftus, Jr. , Sandborn W. J., Bryant S. C., and Smyrk T. C., “Methylation Status of Genes in Non‐Neoplastic Mucosa From Patients With Ulcerative Colitis‐Associated Colorectal Cancer,” American Journal of Gastroenterology 105 (2010): 1610–1619, 10.1038/ajg.2010.22. [DOI] [PubMed] [Google Scholar]
- 102. Shen L., Catalano P. J., A. B. Benson, III , O'Dwyer P., Hamilton S. R., and Issa J. P. J., “Association Between DNA Methylation and Shortened Survival in Patients With Advanced Colorectal Cancer Treated With 5‐Fluorouracil Based Chemotherapy,” Clinical Cancer Research 13 (2007): 6093–6098, 10.1158/1078-0432.Ccr-07-1011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103. de Maat M. F., Umetani N., Sunami E., Turner R. R., and Hoon D. S., “Assessment of Methylation Events During Colorectal Tumor Progression by Absolute Quantitative Analysis of Methylated Alleles,” Molecular Cancer Research 5 (2007): 461–471, 10.1158/1541-7786.Mcr-06-0358. [DOI] [PubMed] [Google Scholar]
- 104. Nishida N., Nagasaka T., Nishimura T., Ikai I., Boland R. C., and Goel A., “Aberrant Methylation of Multiple Tumor Suppressor Genes in Aging Liver, Chronic Hepatitis, and Hepatocellular Carcinoma,” Hepatology 47 (2008): 908–918, 10.1002/hep.22110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 105. Wodarz A. and Näthke I., “Cell Polarity in Development and Cancer,” Nature Cell Biology 9 (2007): 1016–1024, 10.1038/ncb433. [DOI] [PubMed] [Google Scholar]
- 106. Andersen D. S., Colombani J., Palmerini V., et al., “The Drosophila TNF Receptor Grindelwald Couples Loss of Cell Polarity and Neoplastic Growth,” Nature 522 (2015): 482–486, 10.1038/nature14298. [DOI] [PubMed] [Google Scholar]
- 107. McCaffrey L. M. and Macara I. G., “Epithelial Organization, Cell Polarity and Tumorigenesis,” Trends in Cell Biology 21 (2011): 727–735, 10.1016/j.tcb.2011.06.005. [DOI] [PubMed] [Google Scholar]
- 108. Halaoui R. and McCaffrey L., “Rewiring Cell Polarity Signaling in Cancer,” Oncogene 34 (2015): 939–950, 10.1038/onc.2014.59. [DOI] [PubMed] [Google Scholar]
- 109. Warner S. J., Yashiro H., and Longmore G. D., “The Cdc42/Par6/aPKC Polarity Complex Regulates Apoptosis‐Induced Compensatory Proliferation in Epithelia,” Current Biology 20 (2010): 677–686, 10.1016/j.cub.2010.03.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 110. Macara I. G. and McCaffrey L., “Cell Polarity in Morphogenesis and Metastasis,” Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 368 (2013): 20130012, 10.1098/rstb.2013.0012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111. Leggett S. E., Hruska A. M., Guo M., and Wong I. Y., “The Epithelial‐Mesenchymal Transition and the Cytoskeleton in Bioengineered Systems,” Cell Communication and Signaling 19 (2021): 32, 10.1186/s12964-021-00713-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112. Hanahan D. and Weinberg R. A., “Hallmarks of Cancer: The Next Generation,” Cell 144 (2011): 646–674, 10.1016/j.cell.2011.02.013. [DOI] [PubMed] [Google Scholar]
- 113. Xu Y., Chang R., Peng Z., et al., “Loss of Polarity Protein AF6 Promotes Pancreatic Cancer Metastasis by Inducing Snail Expression,” Nature Communications 6 (2015): 7184, 10.1038/ncomms8184. [DOI] [PubMed] [Google Scholar]
- 114. Sakakibara J., Sakakibara M., Shiina N., et al., “Expression of Cell Polarity Protein Scribble Differently Affects Prognosis in Primary Tumor and Lymph Node Metastasis of Breast Cancer Patients,” Breast Cancer 24 (2017): 393–399, 10.1007/s12282-016-0715-2. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
No datasets were generated or analysed during the current study.
